Fusion Pharmaceuticals Management
Management criteria checks 4/4
Fusion Pharmaceuticals' CEO is John Valliant, appointed in Dec 2014, has a tenure of 9.5 years. total yearly compensation is $2.08M, comprised of 28.7% salary and 71.3% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $6.86M. The average tenure of the management team and the board of directors is 2.8 years and 5.2 years respectively.
Key information
John Valliant
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 28.7% |
| CEO tenure | 9.5yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$2m | US$597k | -US$95m |
| Sep 30 2023 | n/a | n/a | -US$91m |
| Jun 30 2023 | n/a | n/a | -US$98m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$3m | US$595k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$80m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$3m | US$597k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$77m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$7m | US$505k | -US$80m |
| Sep 30 2020 | n/a | n/a | -US$75m |
| Jun 30 2020 | n/a | n/a | -US$65m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | US$1m | US$399k | -US$16m |
Compensation vs Market: John's total compensation ($USD2.08M) is below average for companies of similar size in the US market ($USD5.64M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Valliant (53 yo)
9.5yrs
Tenure
US$2,081,586
Compensation
Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.5yrs | US$2.08m | 0.37% $ 6.9m | |
| President & Chief Business Officer | 2.8yrs | US$1.41m | 0.015% $ 276.8k | |
| CFO & Compliance Officer | 5.3yrs | US$1.30m | 0.012% $ 224.4k | |
| Chief Technology Officer | 2.6yrs | US$1.42m | 0.045% $ 829.5k | |
| Chief Scientific Officer | 2.6yrs | no data | 0.014% $ 257.7k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Legal Officer | 3.8yrs | no data | no data | |
| Senior Vice President of Business Development | 2.8yrs | no data | no data | |
| Chief of Staff | no data | no data | no data | |
| Executive Vice President of Medical Director & Clinical Development | 2.2yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | no data |
2.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: FUSN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.5yrs | US$2.08m | 0.37% $ 6.9m | |
| Independent Chairperson of the Board | 3.7yrs | US$126.49k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$103.49k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$108.24k | 0.066% $ 1.2m | |
| Independent Director | less than a year | US$101.89k | 0% $ 0 | |
| Member of Advisory Board | 5.9yrs | no data | no data | |
| Independent Director | 3.2yrs | US$98.49k | 0% $ 0 | |
| Member of Advisory Board | 5.9yrs | no data | no data | |
| Member of Advisory Board | 5.9yrs | no data | no data | |
| Member of Advisory Board | 5.9yrs | no data | no data | |
| Member of Advisory Board | 5.9yrs | no data | no data | |
| Independent Director | 3.3yrs | US$97.49k | 0% $ 0 |
5.2yrs
Average Tenure
53yo
Average Age
Experienced Board: FUSN's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/06 07:00 |
| End of Day Share Price | 2024/06/04 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusion Pharmaceuticals Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Justin Walsh | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |